Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples

Abstract

Rivaroxaban and dabigatran are new oral anticoagulants (NOACs) that inhibit directly factor Xa and thrombin, respectively. These NOACs effectively prevent thromboembolic complications using fixed doses without the need for dose adjustment according to laboratory results. About 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug. About 80% of dabigatran is excreted into urine as active compound. Accordingly, both NOACs can be determined in urine by means of chromatographic methods. Only a few laboratories are able to perform such methods, and results are not available within short time frames. New methods have to be developed to obtain results within minutes and possibly as point-of-care (POC) techniques. This testing may be useful for special patient populations such as those with acute deterioration of renal function due to any disease, before surgical interventions, during unexpected bleeding or thrombotic episodes while on therapy with NOACs, the oldest and youngest populations, pregnancy, suspicion of overdose and intoxication, and to determine adherence to therapy. Here we describe results of a POC qualitative assay using urine samples from patients on treatment with dabigatran and rivaroxaban.

Keywords

new oral anticoagulants - dabigatran - rivaroxaban - point-of-care method - urine

• References

• 1 Falck-Ytter Y, Francis CW, Johanson NA , et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e278S-e325S
• 2 Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104 (6) 1106-1115
• 3 Linkins LA, Dans AL, Moores LK , et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e495S-530S
• 4 Lip GY, Andreotti F, Fauchier L , et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106 (6) 997-1011
• 5 Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15 (3) 213-216
• 6 Lader E, Martin N, Cohen G , et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?. J Clin Pharm Ther 2012; 37 (4) 375-377
• 7 Harenberg J, Marx S, Krejczy M, Wehling M. New anticoagulants - promising and failed developments. Br J Pharmacol 2012; 165 (2) 363-372
• 8 Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both?. Thromb Haemost 2012; 107 (5) 803-805
• 9 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 8 (4) 621-626
• 10 Harenberg J, Marx S, Erdle S, Krämer R. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012; 5 (1) 107-113
• 11 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
• 12 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49 (5) 755-757
• 13 Anderson JL, Adams CD, Antman EM , et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116 (7) e148-e304
• 14 Tomonaga Y, Gutzwiller F, Lüscher TF , et al. Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial. BMC Fam Pract 2011; 12: 12
• 15 Sidelmann JJ, Gram J, Larsen A, Overgaard K, Jespersen J. Analytical and clinical validation of a new point-of-care testing system for determination of D-dimer in human blood. Thromb Res 2010; 126 (6) 524-530
• 16 Van Cott EM. Point-of-care testing in coagulation. Clin Lab Med 2009; 29 (3) 543-553
• 17 Jespersen J, Poller L, van den Besselaar AM , et al. External quality assessment (EQA) for CoaguChek monitors. Thromb Haemost 2010; 103 (5) 936-941
• 18 Chen F, Maridakis V, O'neill EA , et al. A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel. Platelets 2012; 23 (4) 249-258
• 19 Görlinger K, Dirkmann D, Hanke AA , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (6) 1179-1191
• 20 Kubitza D, Becka M, Mueck W , et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70 (5) 703-712
• 21 Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72 (13) 1739-1753
• 22 Harenberg J, Kraemer R. Direct thrombin inhibitors. International Patent Application No. PCT/EP2012/002540
• 23 Gray E, Harenberg J. ISTH Control of Anticoagulation SSC Working Group on Thrombin Inhibitors. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J Thromb Haemost 2005; 3 (9) 2096-2097
• 24 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
• 25 Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol 1990; 43 (6) 543-549
• 26 Hasnain M, Onishi H, Elstein AS. Inter-rater agreement in judging errors in diagnostic reasoning. Med Educ 2004; 38 (6) 609-616
• 27 Böhning D, Holling H, Patilea V. A limitation of the diagnostic-odds ratio in determining an optimal cut-off value for a continuous diagnostic test. Stat Methods Med Res 2011; 20 (5) 541-550
• 28 Harenberg J, Kraemer R. Direct factor Xa inhibitors. International Patent No. PCT/EP2011/WO2012/06913A1
• 29 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012; 38 (2) 178-184
• 30 Harenberg J, Marx S, Weiss C, Krämer R, Samama M, Schulman S. on behalf of the working party: methods to determine rivaroxaban of the Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10 (7) 1433-1436
• 31 Tripodi A. Problems and solutions for testing hemostasis assays while patients are on anticoagulants. Semin Thromb Hemost 2012; 38 (6) 586-592
• 32 Mahler C, Hermann K, Horne R , et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010; 16 (3) 574-579
• 33 Attema-de Jonge ME, Peeters SY, Franssen EJ. Performance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department. J Emerg Med 2012; 42 (6) 682-691
• 34 Cervinski MA, Lockwood CM, Ferguson AM , et al. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy. Clin Chim Acta 2009; 406 (1-2) 81-85
• 35 Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27 (5) 1218-1224
• 36 Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005; 22 (2) 163-171
• 37 Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003; 35 (3) 207
• 38 Horne R, Weinmann J, Barber N. Concordance, Adherence and Compliance in Medicine Taking. London, England: National Co-ordinating Centre for NHS Service Delivery and Organisation Research and Development (NCCDSO); 2005
• 39 Tabrizi JS, Wilson AJ, Coyne ET, O'Rourke PK. Clients' perspective on service quality for type 2 diabetes in Australia. Aust N Z J Public Health 2007; 31 (6) 511-515
• 40 Kaplan SH, Greenfield S, Ware Jr JE. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 1989; 27 (3, Suppl) S110-S127
• 41 Delaney BC, Hyde CJ, McManus RJ , et al. Systematic review of near patient test evaluations in primary care. BMJ 1999; 319 (7213) 824-827